The company's lead product, AUVELITY for major depressive disorder (MDD), has been exceeding sales expectations ... and sustain long-term growth. This analysis is based on information available ...

The company's lead product, AUVELITY for major depressive disorder (MDD), has been exceeding sales expectations, while multiple late-stage clinical trials ... These advantages could allow Axsome to ...

Comprehensive SWOT analysis reveals key strengths ... MCHP demonstrated resilience. The company's net sales for the quarter stood at $1,163.8 million, a decrease from the previous year's $2,254.3 ...